Trials / Completed
CompletedNCT04643470
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Zanubrutinib in Patients With Active Proliferative Lupus Nephritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 177 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Administered as specified in the treatment arm |
| DRUG | Placebo | Placebo to match zanubrutinib |
Timeline
- Start date
- 2020-12-22
- Primary completion
- 2024-02-26
- Completion
- 2024-08-26
- First posted
- 2020-11-25
- Last updated
- 2024-11-29
Locations
44 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04643470. Inclusion in this directory is not an endorsement.